Abstract
The two-domain vascular drug constructs are selective anti-cancer agents capable of specific targeting and subsequent elimination of endothelial cells lining tumor blood vessels. The destruction of existing vasculature within tumor tissue causes insufficient oxygenation of adjacent neoplastic cells and their necrotic death. The recognition (cognitive) domain of the vascular disruptive agents is responsible for recognizing markers specific for endothelial cells. This domain can be formed by variable regions of antibodies or by suitable ligands (such as those binding various integrin or growth factor receptors). The effector domain, in turn, can be constructed from proteins participating in blood clotting process, as well as from toxins, cytokines, radioactive isotopes or pro-apoptotic factors. This article outlines issues important for constructing such two-domain vascular disruptive agents and emphasizes the modularity of their assembly. Several pharmacokinetic and pharmacodynamic properties of these novel agents are discussed. Compared to known cytostatic substances exerting anti-angiogenic effects, such vascular disruptive agents can be much more effective as cytotoxic agents, especially in combination with proven anti-cancer drugs.
Keywords: vascular disruptive agents, tumor vessels, cancer therapy
Current Cancer Drug Targets
Title: Two-Domain Vascular Disruptive Agents in Cancer Therapy
Volume: 4 Issue: 6
Author(s): Stanislaw Szala
Affiliation:
Keywords: vascular disruptive agents, tumor vessels, cancer therapy
Abstract: The two-domain vascular drug constructs are selective anti-cancer agents capable of specific targeting and subsequent elimination of endothelial cells lining tumor blood vessels. The destruction of existing vasculature within tumor tissue causes insufficient oxygenation of adjacent neoplastic cells and their necrotic death. The recognition (cognitive) domain of the vascular disruptive agents is responsible for recognizing markers specific for endothelial cells. This domain can be formed by variable regions of antibodies or by suitable ligands (such as those binding various integrin or growth factor receptors). The effector domain, in turn, can be constructed from proteins participating in blood clotting process, as well as from toxins, cytokines, radioactive isotopes or pro-apoptotic factors. This article outlines issues important for constructing such two-domain vascular disruptive agents and emphasizes the modularity of their assembly. Several pharmacokinetic and pharmacodynamic properties of these novel agents are discussed. Compared to known cytostatic substances exerting anti-angiogenic effects, such vascular disruptive agents can be much more effective as cytotoxic agents, especially in combination with proven anti-cancer drugs.
Export Options
About this article
Cite this article as:
Szala Stanislaw, Two-Domain Vascular Disruptive Agents in Cancer Therapy, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332826
DOI https://dx.doi.org/10.2174/1568009043332826 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry 2D-Gel Electrophoresis Analysis of Proteomic Changes in Three Human Cell Lines; HEK 293, HepG2 and 1321N1 Cells in Response to Cadmium
Current Proteomics Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Callitris intratropica R.T. Baker & H.G. Smith as a Novel Rich Source of Deoxypodophyllotoxin
Current Bioactive Compounds Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Convection-Enhanced Delivery: Neurosurgical Issues
Current Drug Targets 3D QSAR Studies of Tricyclic Compounds as Porcupine Inhibitors for Wnt Pathway Inhibitory Activity
Letters in Drug Design & Discovery Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Current Cancer Drug Targets Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences Medicinal Electrochemistry: Integration of Electrochemistry, Medicinal Chemistry and Computational Chemistry
Current Medicinal Chemistry Hapten Recognition by T Cells: A Functional and Molecular View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry